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IL-2 is a growth factor for T cells and drives 
these cells to proliferate and differentiate into ef-
fector cells. IL-2 predominantly activates cells 
expressing high-affinity receptors composed of 
three chains (IL-2R [CD25], IL-2R [CD122], 
and c [CD132]), such as activated CD4+ and 
CD8+ T cells, but can also activate cells with 
low-affinity  IL-2Rs, such as memory-phe-
notype (MP) CD8+ cells and NK cells (1–3). In 
the case of CD4+ cells,  IL-2Rs are consti-
tutively expressed by T regulatory cells (T reg 
cells), which, through expression of the tran-
scription factor Foxp3, inhibit the function of 
other cells (4, 5). T reg cells are crucially depen-
dent on IL-2 for their growth and survival (6, 7), 
and can be eliminated by the injection of neu-
tralizing anti–IL-2 mAb (8, 9).
Selective enrichment of T reg cells has the 
potential to treat autoimmune disease and impair 
transplant rejection, and there is considerable in-
terest in the idea of injecting T reg cells after 
previous expansion in vitro (10–12). An alterna-
tive approach would be to expand T reg cells in 
vivo. We have recently devised a method for in-
ducing selective expansion of T reg cells under 
in vivo conditions in mice (13). This technique 
stemmed from the finding that the biological ac-
tivity of IL-2 in vivo could be greatly enhanced 
by association with anti–IL-2 mAbs. For most 
IL-2 mAbs tested, injecting IL-2–mAb com-
plexes led to marked and selective proliferation 
of MP CD8+ cells and NK cells, i.e., cells ex-
pressing low-affinity  IL-2Rs. However, with 
one particular IL-2 mAb, JES6-1, injection of 
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Via a transcription factor, Foxp3, immunoregulatory CD4+CD25+ T cells (T reg cells) play an 
important role in suppressing the function of other T cells. Adoptively transferring high 
numbers of T reg cells can reduce the intensity of the immune response, thereby providing 
an attractive prospect for inducing tolerance. Extending our previous findings, we describe 
an in vivo approach for inducing rapid expansion of T reg cells by injecting mice with 
interleukin (IL)-2 mixed with a particular IL-2 monoclonal antibody (mAb). Injection of 
these IL-2–IL-2 mAb complexes for a short period of 3 d induces a marked (>10-fold) 
increase in T reg cell numbers in many organs, including the liver and gut as well as the 
spleen and lymph nodes, and a modest increase in the thymus. The expanded T reg cells 
survive for 1–2 wk and are highly activated and display superior suppressive function. 
Pretreating with the IL-2–IL-2 mAb complexes renders the mice resistant to induction of 
experimental autoimmune encephalomyelitis; combined with rapamycin, the complexes can 
also be used to treat ongoing disease. In addition, pretreating mice with the complexes 
induces tolerance to fully major histocompatibility complex–incompatible pancreatic islets 
in the absence of immunosuppression. Tolerance is robust and the majority of grafts are 
accepted indefinitely. The approach described for T reg cell expansion has clinical potential 
for treating autoimmune disease and promoting organ transplantation.
© 2009 Webster et al. This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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the periphery, adoptive transfer of CFSE-labeled cells followed 
by injection of IL-2–JES6-1 mAb showed that the increase in 
numbers of T reg cells reflected substantial division in extra-
thymic sites rather than increased release of these cells from the 
thymus (Fig. 1 F). Proliferation was minimal with the transfer 
of CFSE-labeled resting CD4+CD25 cells, indicating that the 
increase in T reg cell numbers did not reflect conversion from 
other CD4+ cells.
Kinetics studies showed that T reg cell expansion after the 
three injections was rapid but quite brief, reaching a peak on 
day 5 and then declining rapidly to approach background 
levels by approximately day 15. These findings refer to cells 
in the spleen and apply to both the percentage of T reg cells 
(Fig. 1 G, left) and the total numbers of these cells (Fig. 1 G, 
right). Disappearance of most of the expanded cells by week 
2 also applied to the liver, gut, and other tissues (unpublished 
data). T reg cell expansion was blocked by coinjection of 
CD25 mAb (PC61), indicating stimulation via high-affinity 
 IL-2Rs (Fig. 1 G, left). In contrast, expansion of cells 
expressing the weaker  IL-2Rs, namely MP CD8+ cells 
and NK cells, was minimal (Fig. 1 H).
With regard to surface phenotype, IL-2–JES6-1 mAb–ex-
panded T reg cells in the spleen tested at 1 d after the injections 
(day 3) showed a considerable increase in the expression of mol-
ecules crucial to suppression, such as CD25, glucocorticoid- 
induced TNFR (GITR), cytotoxic T lymphocyte antigen 4 
(CTLA-4), and inducible T cell co-stimulator (ICOS), and 
smaller increases in several other markers relative to T reg cells 
from control mice (Fig. 2 A); in contrast, injection of IL-2 
alone had little or no effect on T reg cell phenotype. This 
highly activated state was brief, as by day 7 the majority of these 
molecules had returned to near-normal levels of expression 
(unpublished data). When their functional activity was tested 
by restimulation in vitro with CD3 mAb and IL-2, the ex-
panded T reg cells showed enhanced synthesis of IL-10 mRNA 
but little change in TGF- (Fig. 2 B). The activated pheno-
type of the IL-2–JES6-1 mAb–expanded T reg cells, in addi-
tion to the known IL-10–dependent inhibitory function of 
Foxp3+ cells (15), was indicative of a possible superior suppres-
sive function. This was indeed the case. Thus, IL-2–JES6-1 
mAb–expanded T reg cells were more effective than normal 
or IL-2–stimulated T reg cells not only at inhibiting prolifer-
ation of normal CD4+ cells in response to CD3 ligation in 
vitro (Fig. 2 C), but also in blocking homeostatic prolifera-
tion of naive CD4+ cells in immunodeficient RAG/ hosts 
(Fig. 2 D). Nevertheless, the superior suppressive effect of the 
expanded T reg cells was transient and had largely disappeared 
by day 7 (5 d after the last of the three injections).
Expansion of T reg cells impairs EAE induction
In view of evidence that T reg cells can impair immune re-
sponses of T cells in vivo (16, 17), we tested whether the ex-
pansion of T reg cells induced by IL-2–JES6-1 mAb injection 
could be used to inhibit the induction of T cell–mediated 
autoimmune disease. On this point, a recent study showed 
that continuous treatment of female nonobese diabetic mice 
IL-2–mAb complexes caused selective expansion of T reg cells 
with little or no change in other cells. Recently, this approach 
was used successfully to treat asthma in a mouse model (14). In 
this report, we have defined the features of T reg cells ex-
panded by IL-2–JES6-1 injections and present evidence that 
mice pretreated with these complexes are resistant to the in-
duction of experimental autoimmune encephalomyelitis (EAE) 
and show long-term acceptance of MHC-incompatible pan-
creatic islet allografts.
RESULTS AnD DISCUSSIOn
Features of T reg cells expanded by IL-2–JES6-1 injection
Previous evidence on T reg cell expansion after IL-2–JES6-1 
injection was limited to the finding that daily i.p. injections of 
these complexes for 1 wk led to a mild (threefold) increase 
in the proportion of CD4+CD25+Foxp3+ cells in the spleen 
(13). For these studies, a fourfold molar excess of mAb was 
used, i.e., 1.5 µg (87 pmol) IL-2 and 50 µg (330 pmol) mAb. 
To optimize the yield of T reg cells, we tested the effects of 
injecting different proportions of IL-2 and JES6-1 mAb. With 
three daily injections (days 0, 1, and 2) of IL-2 (1 µg/58 pmol) 
mixed with titrated concentrations of mAb, maximal T reg 
cell expansion in the spleen 1 d later (day 3) was observed 
with around 5 µg (33 pmol) mAb per injection, which was 
equivalent to an 1:2 molar ratio of mAb/IL-2, with neither 
reagent in excess (Fig. 1 A). With this ratio, the proportion of 
CD4+ cells with a CD25+Foxp3+ phenotype rose to 50–60% 
compared with the baseline level of 5–10% in control mice. 
Increasing the total dose of mAb and IL-2 at this fixed 1:2 
molar ratio resulted in a maximum T reg cell yield of 80% of 
the CD4+ population (Fig. 1 B). A total dose of 6 µg per in-
jection (5 µg mAb + 1 µg IL-2) gave near optimal T reg cell 
expansion and was chosen for all subsequent experiments.
At the optimal 1:2 ratio of JES6-1 mAb/IL-2, three daily 
injections of 6 µg led to a marked 10–20-fold increase in total 
numbers of T reg cells in the spleen on day 5. Injection of IL-2 
alone caused only a very mild (50%) increase in T reg cells, 
which was not enhanced by coinjection with an isotype con-
trol (IC) mAb (Fig. 1 C and Fig. S1). When JES6-1 mAb was 
added in molar excess, T reg cell expansion by IL-2 was less 
marked (Fig. 1 A), a finding in concordance with in vitro data 
on the mild neutralizing effect of JES6-1 mAb on IL-2 presen-
tation to high-affinity IL-2Rs (13). Similarly, injection of 
JES6-1 mAb alone caused a twofold reduction in the number 
of T reg cells, presumably reflecting neutralization of low lev-
els of endogenous IL-2 (Fig. 1 C and Fig. S1).
Interestingly, the substantial increase in T reg cells ob-
served after injection of IL-2–JES6-1 mAb was widespread, 
being also observed in the mesenteric LNs, liver, and BM, as 
well as Peyer’s patches (PP) and the lamina propria (LP) of the 
gut; T reg cell expansion was especially prominent in the liver 
and LP (Fig. 1 D). There was also a moderate (threefold) in-
crease in T reg cells in the thymus (Fig. 1 E). A comparable 
increase in CD4+CD8+ double-positive Foxp3+ precursors 
implies that, at least in part, the expansion of thymic single-
positive CD4+Foxp3+ cells occurred in situ. For T reg cells in 
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Figure 1. Rapid and widespread proliferation of T reg cells after IL-2–JES6-1 treatment. Mice were injected i.p. daily for 3 d (days 0, 1, and 2) 
with JES6-1 mAb and/or IL-2 and analyzed on day 3 (A and B), day 5 (C–E), day 6 (F), or where indicated (G and H), usually in the spleen. Doses were 1 µg 
IL-2 and 5 µg mAb unless otherwise specified. (A) The effect of varying the ratio of IL-2 and JES6-1 on CD4+CD25+Foxp3+ (T reg cell) expansion was ana-
lyzed by injecting titrated doses (1–50 µg) of JES6-1 mAb, plus a fixed concentration (1 µg) of rmIL-2. The arrow indicates a 1:2 molar ratio of JES6-1 
mAb to IL-2. (B) The effect of titrating the dose of IL-2 plus JES6-1 mAb (molar ratio constant at 2:1) was analyzed by varying the total dose from 0–24 
µg per day. (C) The total numbers of T reg cells in the spleen were enumerated after treatment with JES6-1, IC mAb (rat IgG2a), IL-2, IL-2–IC mAb, or IL-2–
JES6-1 mAb. Horizontal bars represent means. (D) Expansion of T reg cells in the spleen, MLN, liver, BM, PP, and small intestinal LP after injection of IL-2–
JES6-1. (E) Number of Foxp3+ cells in the CD4+ single-positive and CD4+CD8+ double-positive thymocyte populations after IL-2–JES6-1 treatment.  
(F) Proliferation, as measured by CFSE dilution, of adoptively transferred CD4+CD25+ or CD4+CD25 Ly5.1+ T cells in LNs of mice injected with IL-2–JES6-1. 
Percentages of donor cells divided (as determined by CFSE incorporation) are shown. (G) Kinetics of T reg cell expansion in the spleen after three injec-
tions of IL-2–JES6-1. Percentages (left) and total cell numbers (right) are shown. The percentage of Foxp3+ cells after 200 µg PC61 i.p. (day 1) followed 
by three injections of IL-2–JES6-1 is shown (arrows). (H) Expansion of cells with the  IL-2R, MP CD8+ T cells and NK cells, compared with T reg cells 
( IL-2R) after IL-2–JES6-1 treatment. Data are shown as a fold change for each cell type compared with untreated mice over 9 d (the dashed line 
indicates a fold change of 1). Data in A, B, D, and G (left) are shown as percentages of CD4+ T cells. Data are representative of two to five independent 
experiments. Data are means ± SEM. Flow cytometry plots depict log10 fluorescence.
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mild neurological symptoms of EAE. No protection against 
EAE induction occurred when mice were pretreated with 
IL-2 alone.
The described experiment indicated that expanding T reg 
cells in mice led to strong resistance to subsequent induction 
of EAE. However, the clinical relevance of these findings is 
questionable because MS patients have an ongoing immune 
response. Hence, the effect of therapeutic administration of 
IL-2–JES6-1 mAb complexes on EAE progression was ex-
amined. When mice were immunized with MOG peptide 
with IL-2–JES6-1 for 10 wk prevented the onset of diabetes 
(18). We examined whether short-term (3-d) treatment of 
C57BL/6 mice with IL-2–JES6-1 mAb could impair in-
duction of EAE, a model for multiple sclerosis (MS). EAE 
was induced by injection of an immunogenic peptide of 
myelin oligodendrocyte glycoprotein (MOG35-55) in CFA 
(19). As expected, control C57BL/6 mice all developed 
severe disease by 14 d after MOG/CFA injection and had 
to be culled within 3 wk (Fig. 3 A). Significantly, pretreat-
ing the mice for 3 d with IL-2–JES6-1 mAb led only to 
Figure 2. Phenotype of IL-2–JES6-1–expanded T reg cells. Mice were treated on days 0, 1, and 2 with 1 µg/5 µg IL-2–JES6-1, 1 µg IL-2, or PBS, 
and the phenotype of the expanded T reg cells was analyzed on day 3 or 7, as described. (A) Splenic CD4+CD25+Foxp3+ T reg cells were analyzed on day 3 
by flow cytometry for expression of cell-surface molecules, CD25, GITR, TGF-, ICOS, CD44, CD103, ICAM-1, and PD-1, and intracellular molecules, Foxp3, 
and CTLA-4. (B) Quantification of IL-10 and TGF- mRNA after in vitro restimulation of FACS-sorted CD4+CD25+ or CD4+CD25 T cells isolated from mice 
on day 3 after treatment (reference gene, 18s RNA). (C) In vitro suppression of CD4+CD25 T cells (effectors) by FACS-sorted CD4+CD25+ T reg cells (sup-
pressors; in indicated ratios) isolated from mice on day 3 or 7 after treatment. Proliferation of effectors was measured by incorporation of [3H]thymidine. 
(D) In vivo suppression of homeostatic proliferation of CD4+CD25 Thy1.1+ T cells adoptively transferred into RAG/ hosts in a 1:1 ratio with CD4+CD25+ 
T reg cells isolated from C57BL/6 mice on day 3 after treatment. Thy1.1+ cell numbers were determined on day 7 after transfer. Data are representative of 
two to three independent experiments. Data are means ± SEM. Flow cytometry plots depict log10 fluorescence.
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Figure 3. Impaired induction of EAE in mice treated with IL-2–JES6-1. EAE was induced on day 0 by immunization of MOG35-55 in CFA. Mice 
were treated with combinations of 1 µg IL-2, 5 µg JES6-1, and 1 mg/kg rapamycin, as described (n = 8–10 per group). (A) Disease score of mice treated on 
days 3, 2, and 1 with PBS, IL-2, or IL-2–JES6-1. (B) Disease score of mice treated with PBS, IL-2, or IL-2–JES6-1 at the onset of symptoms (typically 
days 7, 8, and 9). (C) Disease score of mice treated with PBS, IL-2–JES6-1 (days 2, 3, and 4), rapamycin (days 2, 3, and 4), or IL-2–JES6-1 (days 2, 3, and 4) 
plus rapamycin (days 2, 3, and 4). The treatment groups in C were further analyzed in D and E. (D) The number of CD4+IL-17+ (triangles) and CD4+IFN-+ 
(diamonds) in the draining LNs and spinal cords of mice at day 12 after MOG immunization. For the draining LNs, the percentage of cytokine-producing 
CD4+ cells for the four groups ranged from a mean of 1.5–2% for IL-17A+ cells and 2.5–3% for IFN-+ cells; for the spinal cord, the mean percentage of 
positive cells in the control group was 11% for IL-17A+ cells and 43% for IFN-+ cells; and in the rapamycin group the mean was 5% for IL-17A+ cells and 
30% for IFN-+ cells (n = 8–9 per group). (E) T reg cells quantified as cell numbers (top) and percentages (bottom) of CD4+ T cells in the draining LNs and 
spinal cords of mice at days 7 and 12 after MOG immunization (n = 5 per group). Data are representative of two to three independent experiments. Data 
are means ± SEM (A–C). Symbols represent individual mice and horizontal bars represent means in D and E. #, mice euthanized for ethical reasons.
and treated with IL-2–JES6-1 mAb for 3 d after disease onset 
(days 7–9), there was no protection and the mice all devel-
oped severe disease (Fig. 3 B).
This finding was not unexpected because, like T reg cells, 
activated effector T cells express high-affinity IL-2Rs. Hence, 
injection of IL-2–JES6-1 mAb after EAE induction presumably 
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These findings on EAE induction suggest that short-term 
treatment with IL-2–JES6-1 mAb complexes plus rapamycin 
after MOG immunization is highly effective in blocking dis-
ease. Because T reg cells failed to enter the spinal cord of the 
protected group, the expanded T reg cells presumably acted 
peripherally, apparently by somehow impairing homing of 
effector cells to the CNS. The relevance of the data to the 
treatment of MS remains to be investigated.
Expansion of T reg cells prevents rejection  
of pancreatic islet allografts
The data on EAE induction indicate that, in the absence of 
immunosuppression, the inhibitory activity of T reg cells was 
most effective when these cells were expanded before, rather 
than after, activation of effector cells. It would therefore fol-
low that previous expansion of T reg cells might be particu-
larly effective in preventing rejection of organ allografts. In 
fact, there are several reports demonstrating that allograft re-
jection can be delayed by the infusion of in vitro–expanded T 
reg cell populations, both polyclonal and antigen specific (11, 
12, 23), or in transgenic mice in which T reg cell numbers are 
constitutively elevated (24). In contrast, attempts at expand-
ing T reg cells in vivo for transplantation tolerance have re-
quired either a lymphopenic environment for expansion 
(11) or combination with immunosuppression (25) for suc-
cess. To examine this issue, we tested the effects of T reg 
cell expansion on the rejection of allogeneic pancreatic is-
lets. In this case, C57BL/6 (H2b) mice were first treated with 
streptozotocin to destroy pancreatic insulin-secreting  cells. 
Once diabetic (as indicated by elevated blood glucose levels; 
BGLs), the mice were treated for 3 d with IL-2–JES6-1 mAb 
complexes (days 3, 2, and 1) as in the above experi-
ments. 1 d later (day 0), the mice were grafted under the kid-
ney capsule with fully MHC-mismatched BALB/c (H2d) islets 
by standard techniques (26).
As expected, blood glucose measurement showed that 
PBS-treated control mice all rejected their grafts rapidly with 
a mean survival time of 17 d (n = 12; Fig. 4 A). Pretreating 
the mice with IL-2 alone had no demonstrable effect on graft 
survival (mean survival time of 16.5 d; n = 4). In marked con-
trast, pretreatment with IL-2–JES6-1 mAb complexes led to 
prominent long-term graft survival. A small proportion of the 
mice rejected their grafts around days 20–25, but the remain-
ing 82% (n = 28 out of 34) of the mice retained their grafts 
indefinitely (>100 d), until they were eventually used for 
other experiments (see below). In fact, for a total of 34 mice 
tested in nine separate experiments, not a single graft was re-
jected after day 25. Histology of long-term grafts revealed 
well-preserved islets with robust insulin production in situ 
and negligible leukocyte infiltration. Only minor, peri-islet 
mononuclear accumulations were observed (Fig. 4 B, arrow). 
To confirm that euglycemia and inferred long-term graft ac-
ceptance were indeed graft dependent, a nephrectomy was 
performed of the graft-bearing kidney after day 100. All mice 
(n = 5) rapidly reverted to hyperglycemia (Fig. S2), verifying 
their graft dependence for insulin production.
led to the expansion of effector T cells as well as T reg cells, 
thereby neutralizing the protective effects of the latter. To try 
to circumvent this problem, we studied the effects of coinject-
ing rapamycin, which is reported to inhibit proliferation of T 
effector cells while allowing, or even enhancing, the prolifera-
tion of T reg cells (20). Thus, after EAE induction, mice were 
treated with IL-2–JES6-1 mAb, rapamycin, or both for 3 d, 
starting on day 2 after priming, i.e., during the early stages of 
the immune response. Treatment at this time point was chosen 
in an effort to more closely resemble a therapeutic intervention 
during remission rather than active disease of MS patients. With 
this regimen, injecting either rapamycin or IL-2–JES6-1 mAb 
alone delayed the onset of clinical symptoms, but all of the mice 
eventually developed severe disease (Fig. 3 C). In contrast, the 
combined treatment of rapamycin and IL-2–JES6-1 mAb re-
sulted in a marked reduction in disease severity, indicating a 
strong therapeutic effect.
To investigate the mechanism of suppression, we exam-
ined T cell subsets in the spleen, draining LNs and spinal 
cord. Because EAE is mediated in part by local release of 
IFN- and IL-17 in the central nervous system (CNS) (21, 
22), cells synthesizing these cytokines were quantitated after 
restimulation in vitro. When CD4+ cells were examined on 
day 7 after immunization, significant numbers of IFN-+ and 
IL-17+ cells were found in the draining LNs and spleen (un-
published data), and were most prominent in the group 
treated with IL-2–JES6-1 mAb alone, presumably reflecting 
IL-2 stimulation via their high-affinity IL-2Rs. At this early 
stage, neurological symptoms were not yet detectable and 
very few cells were found in the spinal cord. By day 12 after 
immunization, IFN-+ and IL-17+ cells were prominent in 
the spinal cord of the control mice and those given rapamy-
cin alone (Fig. 3 D); the presence of these cells in the spinal 
cord correlated with the onset of symptoms and paralleled a 
reduction of cells in the draining LNs, especially in the con-
trol group. In comparison, there was no accumulation of ef-
fector cells in the spinal cord of mice treated with IL-2–JES6-1 
mAb with or without rapamycin (Fig. 3 D), which correlated 
with the lack of symptoms in these groups. At day 15, how-
ever, the mice given IL-2–JES6-1 mAb without rapamycin 
developed clinical symptoms, and infiltration of effector cells 
in the spinal cord was observed (unpublished data). In con-
trast, combined treatment of IL-2–JES6-1 mAb plus rapamy-
cin inhibited effector cell accumulation in the CNS and the 
mice remained symptom free.
With regard to the distribution of T reg cells, expanded 
numbers were found in the draining LNs and spleen of the 
groups that received IL-2–JES6-1 mAb, and were especially 
prominent in the symptom-free group given the combina-
tion of IL-2–JES6-1 mAb plus rapamycin (Fig. 3 E and not 
depicted); this finding applied both to total numbers of T 
reg cells (Fig. 3 E, top) and the percentage of T reg cells 
(Fig. 3 E, bottom). T reg cells entered the spinal cord of the 
mice that developed symptoms along with effector cells but, 
like the latter, were excluded from entering the spinal cord 
of the symptom-free mice (Fig. 3 E).
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showed little or no evidence of tolerance to BALB/c alloanti-
gens. Also, injection of anti-CD25 mAb to deplete CD25+ cells 
failed to cause graft rejection (Fig. S3). To test the possibility 
that long-term islet graft acceptance had led to a state of “igno-
rance” to the graft, some of the recipients were injected i.v. 
with a large dose of 2 × 107 T-depleted BALB/c spleen cells as 
a source of donor APCs. In this case, 9 out of 11 recipients re-
tained their islet grafts (Fig. 4 E); for the 2 mice that did reject 
their grafts, the mice were tested at <100 d after grafting.
These findings indicated that long-term acceptance of islet 
allografts led to a robust form of operational tolerance in which 
the grafts were not rejected even after strong stimulation of 
The mechanism of tolerance was investigated in vitro and 
in vivo. Mixed lymphocyte reactions revealed that T cells from 
long-term grafted mice retained their capacity to proliferate in 
response to BALB/c spleen cells (versus third party CBA [H2k] 
spleen) in vitro (Fig. 4 C). More importantly, the transfer of 
spleen cells from these long-term grafted mice into immuno-
deficient B6.RAG/ hosts bearing established BALB/c islets 
caused graft rejection in 78% of cases (n = 9; Fig. 4 D). More-
over, grafting three of the long-term grafted mice with BALB/c 
skin led to rapid rejection of these skin grafts (unpublished data). 
Collectively, these findings indicated that, despite long-term 
acceptance of the islet allografts in situ, host lymphoid cells 
Figure 4. Long-term allograft survival in IL-2–JES6-1–treated mice. (A) Streptozotocin-induced diabetic C57BL/6 (H2b) mice were treated with 
PBS (n = 10), 1 µg IL-2 (n = 4), or 1 µg/5 µg IL-2–JES6-1 (n = 34) on three consecutive days (days 3, 2, and 1). On day 0, mice were transplanted 
with BALB/c (H2d) islets, and BGLs were monitored as a measure of graft function and survival. Grafts were considered rejected after two consecutive BGLs 
>16 mmol/liter after a period of normoglycemia. Cumulative data from nine independent experiments are shown. (B) Representative hematoxylin-eosin–
stained islet graft under the kidney capsule (>100 POD; left), islet graft stained for insulin (middle), and graft with minor peri-islet mononuclear accumula-
tion (arrow; right; n = 5). (C) Mixed lymphocyte reaction using T cells from long-term engrafted mice or control naive mice as responders, and syngeneic 
C57BL/6, donor BALB/c, or third party CBA/Ca-irradiated splenocytes as stimulators. The proliferation of responders was measured by incorporation of 
[3H]thymidine. Data are means ± SEM. (D) Survival of BALB/c islet grafts in B6.RAG/ hosts after adoptive transfer of 2 × 107 splenocytes i.v. from long-
term engrafted mice (n = 9) or control naive C57BL/6 mice (n = 3). (E) Survival of BALB/c islet grafts in C57BL/6 hosts after challenge with BALB/c T-de-
pleted splenocytes at either <100 d (n = 6) or >100 d (n = 5) after grafting. Data are shown as a Kaplan-Meier graft survival (left) or blood glucose 
measurement (the horizontal gray line indicates a BGL of 16 mmol/liter, the threshold for rejection; right). (F) Representative immunohistochemical stain-
ing for Foxp3+ cells in peri-islet mononuclear accumulation (inset; n = 5). Foxp3+ cells are denoted by horseradish peroxidase staining (arrowheads). I, islet 
graft. Data are representative of three independent experiments unless otherwise specified. Bars: (B) 100 µm; (F, left) 750 µm; (F, right) 20 µm.
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CFSE labeling. Lymphocytes were washed once in 0.1% BSA in PBS, and 
labeled with 1 µl of 5 mM CFSE (Invitrogen) at a density of 106 cells/ml 
0.1% BSA in PBS for 10 min at 37°C in the dark. The reaction was stopped 
with RPMI 1640 with 10% FCS and washed twice. To examine the possi-
bility of conversion, 5 × 106 CD4+CD25 cells or 106 CD4+CD25+ cells 
were adoptively transferred to normal immunocompetent B6 hosts; these 
mice were treated with IL-2–JES6-1 on three consecutive days (1 µg/5 µg 
each) and examined for proliferation on day 6.
In vitro suppression assay. Cell-culture media was RPMI 1640 supple-
mented with 10% fetal calf serum, 10 mM Hepes, 1 mM Na pyruvate, 50 
U/ml penicillin, 50 µg/ml streptomycin, 2 mM l-glutamine, and 55 µm -
mercaptoethanol. CD4+CD25 (responders) and CD4+CD25+ (suppressors) 
cells were purified from spleen and LN suspensions by cell sorting after first 
enriching for CD4+ cells by complement-mediated killing using anti-HSA 
(J11d), anti-IAb (28.16.8S), and anti-CD8 (3.168) and guinea pig comple-
ment (Cedarlane Laboratories). T-depleted splenocytes were used as APCs 
and prepared by complement-mediated killing using anti-Thy1.2 (J1j), fol-
lowed by irradiation (30 Gy). In suppression assays, responders (2 × 104 
cells/well) were cultured in a U-bottom 96-well plate with 8 × 104 APCs 
and 2 µg/ml of soluble anti-CD3 antibody (clone 145-2C11). CD4+CD25+ 
T cells were added to the well in decreasing numbers (responder/suppressor 
ratios = 1:1, 1:1/2, 1:1/4, 1:1/8, 1:1/16, and 1:1/32). Cells were pulsed with 
1 µCi [3H]thymidine (GE Healthcare) per well for the last 8 h of the 72-h 
culture period. All data are shown as mean [3H]thymidine incorporation in 
triplicate cultures.
Quantitative RT-PCR. RNA was isolated from FACS-sorted cells using 
the RNeasy kit (QIAGEN), checked for integrity on a 2100 Bioanalyzer 
(Agilent Technologies), and cDNA synthesized using Superscript III (Invit-
rogen) and random hexamers according to manufacturer’s instructions. Rel-
ative abundance of cDNAs was determined in triplicate by quantitative 
RT-PCR analysis using the ABI Prism 7700 Sequence Detection System 
(Applied Biosystems), with results validity confirmed by samples located in 
the linear range of standard curve analysis. Primer pairs and TaqMan probes 
for IL-10 and TGF- were obtained from Applied Biosystems. Values were 
normalized to 18s rRNA expression in each sample, and fold modulation 
was calculated by a comparative CT method.
Homeostatic proliferation. Congenic Thy1.1+CD4+CD25 T cells and 
Thy1.2+CD4+CD25+ T reg cells from PBS- or IL-2–JES6-1–treated donors 
(three injections of 1 µg/5 µg each) were isolated using MACS columns (Mil-
tenyi Biotec). Cells were mixed in a 1:1 ratio (106 each) and adoptively transferred 
into RAG/ recipient mice. Spleens and LNs were harvested on day 7, and 
the total number of Thy1.1+ T cells was enumerated using flow cytometry.
EAE induction. C57BL/6 mice were immunized subcutaneously (into the 
flanks) with 100 µg MOG35-55 (MEVGWYRSPFSRVVHLYRNGK; Prospec- 
Tany Technogene Ltd.) in CFA containing 400 µg of heat-inactivated Myco-
bacterium tuberculosis H37 RA (Difco) and 25 µg M. butyricum (Difco). They 
received two i.v. injections of 200 ng pertussis toxin (List Biological Labora-
tories, Inc.) on days 0 and 2 after immunization. Animals were monitored 
daily for symptoms and were scored as follows: 0, no disease; 1, loss of tail 
tone; 2, tail paralysis; 3, hind limb weakness; 4, hind limb paralysis; and 5, 
hind limb paralysis and forelimb weakness (19). Mice were euthanized if they 
reached a score >4, according to Garvan Institute guidelines. To investigate 
the effect of IL-2–IL-2 mAb (1 µg/5 µg), mice were injected i.p. daily on 
days 3, 2, and 1 or days 2, 3, and 4, or days 7, 8, and 9 (or at com-
mencement of initial symptoms). Control mice were injected with IL-2 alone 
or PBS. Rapamycin (EMD) was dissolved in 1% wt/vol DMSO and admin-
istered i.p. at a dose of 1 mg/kg on days 2, 3, and 4. To analyze CNS mono-
nuclear cells, mice were perfused and spinal cords were extracted. Lymphocytes 
were separated by a 33% isotonic Percoll gradient at room temperature and 
restimulated in vitro with 100 ng/ml PMA and 2 µg/ml ionomycin for 3.5 h, 
with brefeldin A added after 1 h 20 min of incubation.
nontolerant host T cells by APCs of donor graft origin. Neither 
clonal ignorance nor active suppression appear to be responsible 
for maintaining tolerance in this situation. In particular, as men-
tioned earlier, most T reg cells induced by the IL-2–JES6-1 
mAb injections disappeared rapidly, which makes it unlikely that 
the grafts were maintained by local infiltration with T reg cells. 
This possibility cannot be excluded, however, because in long-
term grafts, scattered T reg cells were detected in the small pock-
ets of lymphoid cells observed adjacent to the grafts (Fig. 4 B, 
arrow; and Fig. 4 F). The role of these Foxp3+ cells is difficult to 
determine in an islet model, although it has been shown in other 
transplantation settings, such as the skin, that T reg cells present 
at the tolerated tissue can prevent rejection (27).
Our data clearly illustrate the potential for using IL-2–
JES6-1 complexes for selectively expanding T reg cells in au-
toimmune disease and organ transplantation. The heightened 
suppressive ability of these expanded cells coupled with the 
widespread upsurge in numbers provides a transient environ-
ment of superior suppression. The finding that short-term 
pretreatment with IL-2–JES6-1 mAb complexes led to the 
indefinite survival of pancreatic islets across the strong BALB/
c→B6 MHC barrier in the absence of immunosuppression 
may have clinical implications for organ transplantation.
MATERIALS AND METHODS
Mice. C57BL/6 (B6), BALB/c, CBA/Ca, and RAG/ (B6 background) 
mice were obtained from the Animal Resources Centre and were used at the 
age of 6–12 wk. Animals were housed under conventional barrier protection 
and handled in accordance with protocols approved by the Garvan Institute 
of Medical Research and St. Vincent’s Hospital Animal Experimentation 
and Ethics Committee, which comply with the Australian code of practice 
for the care and use of animals for scientific purposes.
Injection of IL-2–IL-2 mAb complexes. IL-2–anti–IL-2 mAb (JES6-1) 
complexes were prepared as previously described (13). Recombinant mouse 
IL-2 (PeproTech) was mixed with anti–IL-2 mAb (clone JES6-1; purified 
from hybridomas) and incubated at 37°C for 30 min. Mice were injected i.p. 
Concentrations and duration of injections are specified in Results.
Flow cytometry and antibodies. Cell suspensions of spleen, LNs, thymus, 
PP, and BM were prepared according to standard protocols. Lymphocytes from 
single-cell suspensions of perfused livers were separated by a 33% isotonic Per-
coll density gradient (GE Healthcare). To isolate LP lymphocytes, small intes-
tine segments were treated with PBS plus 5% FCS, 1 mM dithiothreitol, 1 mM 
EDTA, 50 U/ml penicillin, and 50 µg/ml streptomycin to remove epithelial 
cells, after which they were digested in 0.5 mg/ml collagenase and 0.01% 
DNase (Roche) at 37°C; lymphocytes were isolated from the interphase of a 
40%/70% Percoll density gradient. Cell suspensions were stained for FACS 
analysis using the following antibodies (obtained from eBioscience unless other-
wise stated): PE-Cy5.5 anti-CD4 (RM4-5); allophycocyanin or biotin anti-
CD25 (PC61.5); PE or allophycocyanin anti-Foxp3 (FJK-16s); PerCP-Cy5.5 
NK1.1 (PK136; BD); FITC–anti-CD54 (YN1/1.7.4), –anti-CD44 (IM7), 
–anti-CD8 (53-6.7), and –anti–IL-17A (eBio17B7); PE–anti-CD152 (CTLA-4; 
UC10-4B9), –anti-PD1 (J43), –anti-ICOS (7E.17G9; BD), and –anti–IFN- 
(XMG1.2); biotin–anti-CD103 (2E7), –anti-GITR (DTA-1), and –anti-
CD122 (TM-1; BD), and biotin-conjugated chicken anti–TGF- (R&D 
Systems); and FITC–rat IgG2a, FITC–rat IgG2b, PE–rat IgG2a, PE–rat 
IgG2b, biotin–rat IgG2a, PE–Ar Ham IgG1, biotin-conjugated chicken IgY 
(IgG; Jackson ImmunoResearch Laboratories), and Pacific blue streptavidin 
(Invitrogen). Foxp3 staining sets were purchased from eBioscience. Samples 
were analyzed on an LSRII or sorted using a FACSAria (BD). Data were ana-
lyzed using FloJo software (Tree Star, Inc.).
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week until rejection. Graft rejection was defined as an increase of blood glu-
cose to >16 mmol/liter after a period of euglycemia. Nephrectomy was per-
formed a POD ≥100 to determine if the euglycemia was graft dependent.
Assessment of tolerance. To assess donor-specific tolerance, RAG/ 
(H-2b) mice were rendered diabetic with streptozotocin and grafted with 
BALB/c islets, as outlined in the previous section. After 30 d, the mice re-
ceived 2 × 107 spleen cells i.v. from long-term graft survivors or naive age-
matched C57BL/6 controls. To assess immunological ignorance, C57BL/6 
long-term graft survivors were challenged with 2 × 107 T-depleted spleen 
cells from BALB/c mice. Blood glucose was measured to determine the 
outcome of the challenges.
Mixed lymphocyte reaction. T cells from naive and long-term engrafted 
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CD25+ cells after anti-CD25 (PC61) administration, and the subsequent BGL 
and graft maintenance. Online supplemental material is available at http://
www.jem.org/cgi/content/full/jem.20082824/DC1.
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